MRK

SEC source: 0001127602-21-028169 · form4.xml · derivative · entry 7

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,358 shares

Expires 2021-10-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option and time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 2

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,095.087

SEC source: 0001127602-21-028169 · form4.xml · nonDerivative · entry 1

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,257.087

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028165 · form4.xml · derivative · entry 6

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,379 shares

Expires 2024-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017.

F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028165 · form4.xml · derivative · entry 5

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73,026 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

F4 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028165 · form4.xml · nonDerivative · entry 3

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,929.963

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.4550 to $87.8400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028165 · form4.xml · nonDerivative · entry 2

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,334.963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028165 · form4.xml · nonDerivative · entry 1

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,955.963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-028167 · form4.xml · derivative · entry 3

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,213

Underlying: Common Stock · 24,619 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

SEC source: 0001127602-21-028167 · form4.xml · nonDerivative · entry 2

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,145.357

F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to Rule 10b5-1 trading plan.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-028167 · form4.xml · nonDerivative · entry 1

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,764.357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-026161 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,323.5976

Underlying: Common Stock · 432.6987 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-026166 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,121.6864

Underlying: Common Stock · 116.4958 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-026163 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,840.424

Underlying: Common Stock · 216.3494 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-026168 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,899.7801

Underlying: Common Stock · 399.4142 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-021114 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,796.7509

Underlying: Common Stock · 417.8989 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

F4 · balance_after: Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.

SEC source: 0001127602-21-021116 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,571.4316

Underlying: Common Stock · 208.9495 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

F4 · balance_after: Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.

SEC source: 0001127602-21-021118 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,357.7946

Underlying: Common Stock · 112.5113 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

F4 · balance_after: Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.

SEC source: 0001127602-21-021120 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,613.1739

Underlying: Common Stock · 385.7529 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

F4 · balance_after: Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution.

SEC source: 0001127602-21-018647 · form4.xml · derivative · entry 2

BRUN LESLIE A · CIK 0001217068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,719.0553

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018650 · form4.xml · derivative · entry 2

Coe Mary Ellen · CIK 0001691304 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,040.172

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018652 · form4.xml · derivative · entry 2

Craig Pamela J. · CIK 0001232910 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,522.4743

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018654 · form4.xml · derivative · entry 2

GLOCER THOMAS H · CIK 0001140799 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,916.3833

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018656 · form4.xml · derivative · entry 2

LAVIZZO-MOUREY RISA J · CIK 0001034465 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,192.6703

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018658 · form4.xml · derivative · entry 2

Mayo Stephen · CIK 0001849061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,755.2908

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018661 · form4.xml · derivative · entry 2

Rothman Paul · CIK 0001601332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,522.4763

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018665 · form4.xml · derivative · entry 2

Seidman Christine E · CIK 0001805745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,173.1121

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018667 · form4.xml · derivative · entry 2

Thulin Inge G · CIK 0001263739 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,293.0623

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018669 · form4.xml · derivative · entry 2

Warden Kathy J · CIK 0001559112 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,310.1273

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018671 · form4.xml · derivative · entry 2

WENDELL PETER C · CIK 0001032635 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,035.891

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-018726 · form4.xml · derivative · entry 2

RUSSO PATRICIA F · CIK 0001023219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,394.2233

Underlying: Common Stock · 2,635.3933 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-016201 · form4.xml · derivative · entry 4

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,323

Underlying: Common Stock · 19,324 shares

Expires 2023-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016.

SEC source: 0001127602-21-016201 · form4.xml · nonDerivative · entry 2

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,348.057

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $78.42, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-016201 · form4.xml · nonDerivative · entry 1

Clyburn Frank · CIK 0001763963 · EVP & Pres ? Human Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,672.057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-015734 · form4.xml · derivative · entry 3

FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,082

Underlying: Common Stock · 329,082 shares

Expires 2031-05-03

F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015739 · form4.xml · derivative · entry 2

Davis Robert M · CIK 0001363076 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,633

Underlying: Common Stock · 281,633 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015744 · form4.xml · derivative · entry 5

Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,906 shares

Expires 2021-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F5 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

SEC source: 0001127602-21-015744 · form4.xml · derivative · entry 4

Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,633

Underlying: Common Stock · 131,633 shares

Expires 2031-05-03

F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015744 · form4.xml · nonDerivative · entry 2

Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,348.057

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-015744 · form4.xml · nonDerivative · entry 1

Clyburn Frank · CIK 0001763963 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,287.057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-015747 · form4.xml · derivative · entry 2

Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,714

Underlying: Common Stock · 85,714 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015749 · form4.xml · derivative · entry 2

Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, GI Pub Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,796

Underlying: Common Stock · 39,796 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015752 · form4.xml · derivative · entry 3

DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,653

Underlying: Common Stock · 82,653 shares

Expires 2031-05-03

F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015754 · form4.xml · derivative · entry 5

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 694 shares

Expires 2021-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F5 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

SEC source: 0001127602-21-015754 · form4.xml · derivative · entry 4

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,369

Underlying: Common Stock · 2,369 shares

Expires 2024-05-04

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015754 · form4.xml · derivative · entry 3

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,367

Underlying: Common Stock · 18,367 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

SEC source: 0001127602-21-015754 · form4.xml · nonDerivative · entry 2

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,374.346

F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions.

SEC source: 0001127602-21-015754 · form4.xml · nonDerivative · entry 1

LeCointe-Cephas Lisa · CIK 0001854644 · SVP Chief Ethics & Com Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,612.346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-015758 · form4.xml · derivative · entry 4

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,772 shares

Expires 2021-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021.

SEC source: 0001127602-21-015758 · form4.xml · derivative · entry 3

Zachary Jennifer · CIK 0001737231 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,653

Underlying: Common Stock · 82,653 shares

Expires 2031-05-03

F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.